New perspectives in managing myeloprolif
โ
Gunnar Birgegรฅrd
๐
Article
๐
2009
๐
John Wiley and Sons
๐
English
โ 71 KB
## Abstract Risk stratification is the basis for treatment decisions in the chronic myeloproliferative disorders, and in addition to the three established risk factors of previous thrombosis, age and platelets >1500โรโ10^9^, cardiovascular risk factors should be addressed. In addition, premorbidity